Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, net loss was USD 47.52 million compared to USD 41.04 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3725 USD | -3.62% | -90.76% | -92.89% |
05-07 | Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50 | MT |
05-07 | HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy | MT |
1st Jan change | Capi. | |
---|---|---|
-92.89% | 22.71M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |